Human trials of a nasal vaccine to prevent Alzheimer’s to begin

The first clinical trial to test the efficacy of a nasal vaccine to prevent or slow Alzheimer’s disease is about to begin in the United States. According to the trial’s leading physicians at Brigham and Women’s Hospital in Boston, this stage marks the culmination of twenty years of animal testing.

“Over the past two decades, we have accumulated preclinical evidence suggesting the potential of this nasal vaccine for Alzheimer’s disease (AD),” said Dr. Howard Weiner, co-director of the Ann Romney Center, the hospital’s institution. in charge of rehearsals.

The vaccine uses the drug Protollin an agent that allows white blood cells located in the lymph nodes and the back of the neck to migrate to the brain. In this delicate organ, white blood cells will be able to fight a hallmark of Alzheimer’s: protein plaques beta amyloid.

In the hypotheses of scientists, these plaques – also called senile plaques – are toxic to the brain and trigger Alzheimer’s in a healthy person. Also, another candidate protein for causing neurological disease is called tau.

Although this drug has been used in vaccines in the last two decades, its role has been complementary only to enhance the effectiveness of other drugs. For that reason, the Brigham trial will assess Protollin’s efficacy in its own right.

The essay will include 16 participants Come in 60 and 85 years old who have early or symptomatic Alzheimer’s disease, but are generally in good health. All volunteers will receive two doses one week apart as of December 2021 in Boston Weiner said in an interview with the Boston Globe newspaper.

The objective of the Phase I trial will be to determine the safety and tolerability of the nasal vaccine.

“A lot of the other drugs work by giving an antibody, they infuse it into the bloodstream to enter the brain,” Weiner said. “This [vacuna] it’s exciting because it uses the body’s own immune system to fight disease. “

Alzheimer’s disease (AD) is a neurological disorder that progressively impairs memory, thinking, and language. According to the World Health Organization (WHO), it is the most common dementia (between 60% and 70%) and, according to the CDC, it is the leading cause of death in adults over 65 years of age.

Neurological disease has been associated with an “excessive release of inflammatory chemicals” from immune cells of the body. brain synapse failures and even misfolded proteins.

However, although its causes and evolution have been extensively described, there is no cure. Before this disease, the most common treatment is the strengthening of mental function.